Management

Management
Home / About Protalix / Management

Management

Dror Bashan

President & Chief Executive Officer,
Director
-more-

Mr. Bashan has served as our President and Chief Executive Officer and as a director of our company since June 2019.  He has over 20 years of experience in the pharmaceutical industry with roles ranging from business development, marketing, sales and finance providing him with both cross regional and cross discipline experience and a deep knowledge of the global pharmaceutical and health industries.  From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd.  Most recently, he served as Teva’s Senior Vice President, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets.  Mr. Bashan holds a BA in Economics and Business Management from the Tel Aviv University and an MBA from the Tel-Aviv University.

Yoseph Shaaltiel, Ph.D.

Executive Vice President,
Research and Development
-more-

Yoseph Shaaltiel, Ph.D. founded Protalix Ltd. in 1993 and has served as our Executive Vice President, Research and Development since December 2006.  Prior to establishing Protalix Ltd., from 1988 to 1993, Dr. Shaaltiel was a Research Associate at the MIGAL Technological Center.  He also served as Deputy Head of the Biology Department of the Biological and Chemical Center of the Israeli Defense Forces and as a Biochemist at Makor Chemicals Ltd.  Dr. Shaaltiel was a Postdoctoral Fellow at the University of California at Berkeley and at Rutgers University in New Jersey.  He has co-authored over 40 articles and abstracts on plant biochemistry and holds several patents.  Dr. Shaaltiel received his Ph.D. in Plant Biochemistry from the Weizmann Institute of Science, an M.Sc. in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Ben Gurion University.

Einat Brill-Almon, Ph.D.

Senior Vice President,
Product Development
-more-

Dr. Almon joined Protalix Ltd. in December 2004, originally as a Senior Director and later as a Vice President and became our Senior Vice President, Product Development in 2006. Dr. Almon has many years of experience in the management of life science projects and companies, including biotechnology and agrobiotech, with direct experience in clinical, device and scientific software development, as well as a strong background and work experience in intellectual property. Prior to joining Protalix Ltd., from 2001 to 2004, she served as Director of R&D and IP of Medgenics Medical (Israel) Ltd. (formerly, Biogenics Ltd.), a company that developed an autologous platform for tissue-based protein drug delivery. Medgenics Medical, based in Israel, is a wholly-owned subsidiary of Aevi Genomic Medicine, Inc. (formerly, Medgenics Inc.). Dr. Almon has trained as a biotechnology patent agent at leading IP firms in Israel. Dr. Almon holds a Ph.D. and an M.Sc. in molecular biology of cancer research from the Weizmann Institute of Science, a B.Sc. from the Hebrew University and has carried out Post-Doctoral research at the Hebrew University in the area of plant molecular biology.

Eyal Rubin

Senior Vice President & Chief Financial Officer
-more-

Mr. Rubin joined Protalix as its Senior Vice President and Chief Financial Officer in September 2019.  He brings to Protalix more than 20 years of finance and capital markets experience, an extensive background in financial planning and operations, management and strategy and a deep knowledge of the biotechnology and pharmaceutical industries.  Prior to joining Protalix, he served as Executive Vice President and Chief Financial Officer of BrainStorm Cell Therapeutics Inc., a publicly traded biotechnology company, where he was responsible for all corporate finance, accounting and investor relations activities.  Prior to his role at BrainStorm, Mr. Rubin served at Teva Pharmaceutical Industries Ltd. in several roles, most recently as Vice President, Head of Corporate Treasury.  In this role, Mr. Rubin was responsible for Teva’s cash operations and cash management, as well as Teva’s equity and debt capital markets transactions.  Mr. Rubin holds a BA in Financing and IT Systems from the College of Management, Israel, where he graduated Summa Cum Laude with a specialization in Financing and IT Systems, and an MBA from Bar-Ilan University, Israel, where he graduated Summa Cum Laude with a specialization in Finance.

Yaron Naos

Senior Vice President, Operations
-more-

Mr. Naos joined Protalix in 2004, originally as a Senior Director for Operations and later as Vice President for Production, and became our Senior Vice President, Operations in 2018. He has a wealth of hands-on experience and knowledge in the field of pharmaceutical development.  Prior to joining Protalix, he served for a decade as R&D Product Manager at Dexxon Pharmaceutical Co., one of Israel's largest pharmaceutical companies, where he was responsible for technology transfer from R&D to production, and in charge of R&D activities that led to the commercialization of many products.  Later, Mr. Naos was plant manager of Medibrands Pharmaceutical Company, as well as logistics manager of Mediline for period of four years, where he was responsible for all operational activities, from procurement to distribution.  Mr. Naos holds a B.Sc. in Food Engineering and Biotechnology from the Technion-Israel Technology Institute and an MBA from Haifa University.

Moshe Chechik

Vice President, Engineering
-more-
Mr. Moshe Chechik joined Protalix in 2008 as Vice President for Engineering, bringing with him extensive experience in managing, engineering, manufacturing, and leading pharmaceutical projects. Prior to joining Protalix, Moshe served as Infrastructure Development Director at Teva Pharmaceuticals and as an Engineering Manager at the business unit with Teva in North America. Prior to that, he served in the Teva API division as Engineering Manager of a North American business unit. Prior to his career at Teva, Moshe served as Production Manager at Nitron Chemtech Ltd. and Engineering & Maintenance Manager at American Israeli Paper Mills Ltd. He holds a BSc in Chemical Engineering from the Technion-Israeli Institute of Technology and an MBA from Heriot-Watt University.

Michal Kahana, DVM

Vice President, Quality Affairs
-more-
Dr. Michal Kahana joined Protalix in 2009 as Vice President for Quality Affairs with years of experience in QA management in the pharmaceutical industry and broad knowledge of GMP, GLP, and GCP requirements. Prior to joining Protalix, she managed the 85-employee quality department at Dexxon, one of Israel’s largest Pharmaceutical companies, where she guided the company through several FDA, European, and Israeli health authorities inspections. Michal holds a DVM degree from the University of Bologna, Italy.

Dafna Shelly

Vice President, Human Resources
-more-
Ms. Dafna Shelly joined Protalix in November 2010 as Vice President for Human Resources. Prior to joining Protalix, she held a number of executive management positions which combined her scientific and business skills, including over 18 years with Sigma-Aldrich. Her professional studies in the fields of Biology as well as Business Administration and Human Resources give her a wide and comprehensive understanding of both areas, which is important in managing human resources and other facets of a major biotechnology company. Dafna holds an MSc in Brain Research from the Weizmann Institute of Science and an MBA from the Hebrew University of Jerusalem.

Raul Chertkoff, M.D.

Vice President, Medical Affairs
-more-
Dr. Raul Chertkoff worked for over a decade in executive medical management in Klalit Health Services, one of the largest global Health Care Service Organizations. He has served for 10 years as Chairman of the Israeli Gaucher Association and was a co-founder and executive member of the European Gaucher Alliance. Additionally, Raul has vast experience in the Public Health and Clinical Sectors, interacting with doctors and patients in clinical research studies, especially in the field of Gaucher disease. Raul received his MD from the Faculty of Medicine at the Technion-Israel Institute of Technology, and an MBA from the Hebrew University of Jerusalem.

William Taylor

Vice President, Business Development
-more-
Mr. William Taylor joined Protalix in 2015 as Vice President, Business Development. He has thirty-plus years of experience in the Life Sciences/Biopharmaceutical industry, in which he has performed both R&D and Business Development roles. Prior to joining Protalix, he served as Director, Business Development & Commercial Operations with Pfenex, Inc. and as Manager, Strategic Alliances at Pfizer Inc., during which he worked across the global biotech community in roles involving scouting/identification, contract/license negotiation, and alliance management. He holds a M.Sc. in Organic Chemistry from Ohio State University and a B.Sc. in Chemistry from Rochester Institute of Technology.

Ronen Rosenberg

Vice President, Commercial
and Product Planning
-more-
Mr. Ronen Rosenberg joined Protalix in March 2015 as Vice President of Commercial and Product Planning. He brings close to 20 years of experience in the pharmaceutical industry in marketing, sales, commercial and strategic planning, and business development. He held a number of senior managerial positions at Teva Pharmaceutical Industries, including global marketing of Copaxone®, innovative pipeline management and business development, and as Commercial Head of the Global Women’s Health franchise. Prior to his career at Teva, he served as product and marketing manager for leading pharma companies in the local market. Ronen currently lectures on Pharma Marketing at the College of Management Academic Studies’ MBA Biomed track program. Ronen holds a BSc, in Biology from Bar Ilan University and an MBA from Tel Aviv University Recanati Business School.